{"id":756730,"date":"2023-05-09T17:04:00","date_gmt":"2023-05-09T21:04:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/"},"modified":"2023-05-09T17:04:00","modified_gmt":"2023-05-09T21:04:00","slug":"lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/","title":{"rendered":"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WATERTOWN, Mass., May  09, 2023  (GLOBE NEWSWIRE) &#8212; Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 4:35 p.m. PT.<\/p>\n<p align=\"justify\">A live webcast of the presentation will be available on the Investor Relations section of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vgelUbndOY1ECgsNDzrk2Jq3Fd_-_BccjlYHur9iKAlp0nZAQ3872r3szevdBGX4Q2NiSxSLHmmC7RaWqLBT5vf2sV-Klo9_59Rr8kbMaO0xn5ZLn49azMnHdAL1tteF\" rel=\"nofollow noopener\" target=\"_blank\">investors.lyratherapeutics.com<\/a>. Replays of the webcasts will be available for 30 days following the presentation.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Lyra Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kh01wUxsPQprREfPfPsOPKOS-vf2Iq5MDWm3fpXIXAlBIFMlbV_gdwPxoImnR69mjbrNADwCTLyz_aH8yOuOqUqf9qZBJv1li6JHqfvzDitSoDBURL9Bd0BCQeOz4cpe\" rel=\"nofollow noopener\" target=\"_blank\">Lyra Therapeutics<\/a>, Inc. is a clinical-stage biotechnology company developing therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). Lyra has two investigational product candidates, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZRltNPi_wpdhX1NGrgaREnZl3zARANyNXAJPQPO9xh3g2bw_v4HhKSqP2pcfuc1Syxi-TBI3bftV-bdxmOVGCeOrUaEqA6ijZWQsimqo2LQWXzAjA931YRWNqtd4AuCP\" rel=\"nofollow noopener\" target=\"_blank\">LYR-210<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1Rgl98eZ0juCh_cHv-z8DwJaVVFjefMCC5y084UUZT8fbt6OBV00abU4GAy77CqVBalAZ9h0MJXR62aL95bDl1ndJ1o79NlLpVXO4ospy9-BPmOF4EAD2aFGpKKRKjjD\" rel=\"nofollow noopener\" target=\"_blank\">LYR-220<\/a>, in late-stage development for CRS, a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy (7500\u00b5g MF) to the sinonasal passages. LYR-210 is designed for surgically na\u00efve patients and is being evaluated in the ENLIGHTEN Phase 3 clinical program, while LYR-220, an enlarged implant, is being evaluated in the BEACON Phase 2 clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery. These two product candidates are designed to treat the estimated four million CRS patients in the United States who fail medical management each year. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PsKjYvy3MUXEpEdnSRew3o9bWfjTOL394NbTUEqI3wZ_oYR8T88hPeZ15sBgyUVi4bXBhhj4ND6G8kmnG6TXlQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.lyratx.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PdPQO4NjdqyZVrOzIklC2NRNCa-31t-keYqCyzfHNVdhbngVcxJSiiJSKtdy_BWddgZWsNZ48jo07_nldmc7AIw8Jm5HkBSoMkNNtgkjsT0n7G4uryqxcg3ZYu7JnI_k\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Ellen Cavaleri, Investor Relations <br \/>615.618.6228 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Rem9pETJ8F7klOKHS6GJG3Zqtoz9UVyKPY7FsDl2bxhDdj9c54XPr2cZOCNsXts_YSuQZVJPJ9ts8xiuuKcxk8PE3Sj0gMZkLvcdb9k4Y3A=\" rel=\"nofollow noopener\" target=\"_blank\">ecavaleri@lyratx.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzdlMjMyMzMtZDZkOS00NWEzLTkwYTktN2M5NTc2ODk0ZjFkLTEyMDY0MzA=\/tiny\/Lyra-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) &#8212; Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 4:35 p.m. PT. A live webcast of the presentation will be available on the Investor Relations section of the Company&#8217;s website at investors.lyratherapeutics.com. Replays of the webcasts will be available for 30 days following the presentation. About\u00a0Lyra Therapeutics Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). Lyra has two investigational &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-756730","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) &#8212; Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 4:35 p.m. PT. A live webcast of the presentation will be available on the Investor Relations section of the Company&#8217;s website at investors.lyratherapeutics.com. Replays of the webcasts will be available for 30 days following the presentation. About\u00a0Lyra Therapeutics Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). Lyra has two investigational &hellip; Continue reading &quot;Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-09T21:04:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference\",\"datePublished\":\"2023-05-09T21:04:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/\",\"name\":\"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=\",\"datePublished\":\"2023-05-09T21:04:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference - Market Newsdesk","og_description":"WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) &#8212; Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 4:35 p.m. PT. A live webcast of the presentation will be available on the Investor Relations section of the Company&#8217;s website at investors.lyratherapeutics.com. Replays of the webcasts will be available for 30 days following the presentation. About\u00a0Lyra Therapeutics Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). Lyra has two investigational &hellip; Continue reading \"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-09T21:04:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference","datePublished":"2023-05-09T21:04:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/","name":"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=","datePublished":"2023-05-09T21:04:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzNTQzOCM1NTg0ODkxIzIxOTQ4Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyra-therapeutics-to-present-at-bank-of-america-securities-2023-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=756730"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/756730\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=756730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=756730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=756730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}